Health Trials

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

2

Review clinical trials related to Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Participants needed: 150
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: Eidos Therapeutics, a BridgeBio companyUpdated: Jul 29, 2026Locations: 1
Eligibility criteria

Participants aged 18 to 80 [+3]

Current or planned implantation of a cardiac implantable electronic device (eg,... [+6]

Read more
Status: Not yet recruiting

Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis (ATTR) and heart failure with reduced ejection fraction (LVEF ≤40%). The primary objective is to determine the impact of Sac/Vals treatment on systolic function by assessing the change in LVEF on echocardiogram at 12-month follow-up.

Participants needed: 114
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Puerta de Hierro University HospitalUpdated: Dec 2, 2024Locations: 1
Eligibility criteria

Patients ≥ 18 years of age of both sexes. [+3]

NYHA Functional Class IV. [+9]

Read more